Bluejay Diagnostics, Inc. (BJDX) vs Cellyan Biotechnology Co., Ltd (HKPD)
A side-by-side comparison of Bluejay Diagnostics, Inc. and Cellyan Biotechnology Co., Ltd across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BJDX
Bluejay Diagnostics, Inc.
$0.82HealthcareDelayed quote: Oct 6, 2026, 2:17 PM EDT
HKPD
Cellyan Biotechnology Co., Ltd
$0.10HealthcareDelayed quote: Oct 6, 2026, 2:19 PM EDT
Total return — BJDX vs HKPD
growth of $100 · dividends reinvested · last 2yBJDX -94.3% (-76.2%/yr)HKPD -96.3% (-80.8%/yr)BJDX compounded faster over this window
BJDX HKPD
BJDX vs HKPD: by the numbers
- •HKPD is the larger company ($1M vs $849293 market cap).
- •Both run net losses; BJDX's is the smaller (0.00% vs -8.46% net margin).
Metrics side by side
Valuation
| Metric | BJDX | HKPD |
|---|---|---|
| P/B ratio | 0.09 | 0.12 |
Profitability
| Metric | BJDX | HKPD |
|---|---|---|
| Gross margin | 0.00% | 10.32% |
| Operating margin | 0.00% | -7.41% |
| Net margin | 0.00% | -8.46% |
| ROE | -77.23% | -11.85% |
| ROIC | -77.55% | -9.45% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.